Log inSign up
AAOIFI No. 21 screening

Is INM halal?

InMed Pharmaceuticals Inc.

Not halal

InMed Pharmaceuticals Inc. did not pass AAOIFI screening. The failed check is shown below.

Checked: 13 October 2026

Exchange

NASDAQ

Price

1.32

Day

-0.75%

Market cap

$7.5M

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

What the company does

InMed Pharmaceuticals (Vancouver) develops drug candidates from cannabinoid-analog molecules (INM-901 for Alzheimer's, eye disease) and sells rare cannabinoid ingredients via BayMedica. Revenue comes mainly from BayMedica ingredient sales.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $3.70M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $2.19M ÷ 36-month average market cap $3.70M = 59.4%

    59.4%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $7.47M.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Drug Manufacturers - Specialty & Generic — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyINM's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →